Single Use Bioreactors Market Size, Growth and Forecast 2032

Market Overview:

The global single-use bioreactor market is projected to grow significantly, expanding from USD 3,517 million in 2024 to USD 12,953.4 million by 2032, reflecting a robust compound annual growth rate (CAGR) of 17.70% over the forecast period. Single-use bioreactors are increasingly being adopted in biopharmaceutical manufacturing, particularly in the production of vaccines, monoclonal antibodies, and cell therapies. The market's rapid growth is driven by the benefits of disposability, flexibility, and reduced risk of cross-contamination. These reactors allow for cost-effective and faster production processes, especially in clinical trials and commercial manufacturing, making them a preferred choice for biotech companies and contract development and manufacturing organizations (CDMOs).

Several factors drive the growth of the single-use bioreactor market. The increasing demand for biologics, such as monoclonal antibodies and cell-based therapies, is a primary growth driver as biopharmaceutical companies seek scalable and cost-efficient production methods. Single-use bioreactors enable faster turnaround times by eliminating the need for cleaning and sterilization processes, which is crucial for rapid drug development cycles. Additionally, the rise in contract manufacturing organizations (CMOs) adopting single-use technologies supports market expansion, as these organizations focus on meeting the needs of biopharma clients for flexible and scalable production solutions. The adoption of single-use bioreactors is also driven by advances in bioprocessing technologies, which enhance product yield and quality, making single-use systems increasingly viable for commercial production.

Regionally, North America holds the largest share of the single-use bioreactor market, supported by a strong biopharmaceutical industry and high investment in biologics research and development. The United States leads in bioprocessing advancements and has a high adoption rate of single-use technologies among biopharma companies and CMOs. Europe represents a significant market share, driven by robust regulatory support for biologics manufacturing and growth in biosimilars production in countries like Germany and the U.K. The Asia-Pacific region is expected to witness the fastest growth, with countries such as China, India, and South Korea investing heavily in biopharmaceutical manufacturing capabilities. This growth is fueled by increasing government support for biotechnology and a rising number of local players entering the biologics market to meet domestic and international demand.

Market Drivers:

Rising Demand for Biologics and Personalized Medicine:

The increasing prevalence of chronic diseases and the rising demand for biologics, such as monoclonal antibodies and cell therapies, drive the adoption of single-use bioreactors. Biologics account for a significant share of the pharmaceutical pipeline due to their targeted approach and high efficacy in treating complex diseases. For instance, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) notes that biologics make up over 30% of new drug approvals globally. The growth of personalized medicine further amplifies demand, as single-use bioreactors allow for smaller, customized production batches essential in personalized therapies.

Cost-Efficiency and Operational Flexibility:

Single-use bioreactors offer substantial cost savings compared to traditional stainless-steel systems, particularly in setup and maintenance. These systems eliminate the need for cleaning and sterilization, reducing both labor and water usage, which is crucial for operational efficiency. According to a study by the Bio-Process Systems Alliance, single-use technologies can reduce capital costs by 40% or more and shorten production timelines. Companies like Cytiva and Thermo Fisher have reported significant cost reductions and faster batch turnover with single-use systems, making them an attractive option for both established biopharma firms and emerging biotech startups.

Increasing Adoption by Contract Manufacturing Organizations (CMOs):

As biopharmaceutical companies seek flexible and scalable production solutions, contract manufacturing organizations (CMOs) are increasingly adopting single-use bioreactors. CMOs prioritize these systems to accommodate a variety of production needs for multiple clients while minimizing the risk of cross-contamination. For instance, Lonza, a leading CMO, utilizes single-use bioreactors extensively in its facilities, allowing them to streamline operations and quickly transition between different projects. This shift is further supported by data from the Biotechnology Innovation Organization (BIO), which indicates that over 70% of CMOs globally have integrated single-use technologies to meet client demands for high-speed, flexible manufacturing.

Technological Advancements in Bioprocessing:

Advances in bioprocessing technologies are enhancing the efficiency and scalability of single-use bioreactors. New innovations, such as sensor-integrated bioreactors and automated monitoring systems, allow for precise control over parameters like pH, oxygen, and temperature, resulting in higher yield and product quality. Companies like Sartorius have introduced automated single-use systems equipped with real-time analytics, which support process optimization and enable quick adjustments. The U.S. Food and Drug Administration (FDA) has also supported the adoption of these advanced technologies, emphasizing that automation and enhanced control mechanisms can improve production consistency and regulatory compliance.

Market Trends:

Shift Towards Large-Scale Single-Use Bioreactors:

Traditionally used in small to medium-scale production, single-use bioreactors are now being adapted for larger commercial production due to advancements in technology. For instance, Companies like Sartorius and Thermo Fisher have developed large-scale single-use bioreactors that can accommodate volumes of 2,000 liters or more, meeting the needs of biopharma companies looking to scale up production. The Bio-Process Systems Alliance notes that these high-capacity systems are increasingly viable for commercial manufacturing, supporting the trend of shifting away from stainless steel in larger applications.

Integration of Automation and Real-Time Monitoring:

Automation and digitalization are transforming single-use bioreactor operations. Modern systems come equipped with integrated sensors and automated monitoring capabilities that enable precise control over critical parameters like pH, oxygen, and temperature. For example, Cytiva has introduced bioreactors with real-time data analytics, allowing biopharmaceutical companies to enhance process accuracy and reduce variability. According to a survey by the International Society for Pharmaceutical Engineering (ISPE), more than 60% of biopharma companies plan to invest in automated single-use technologies to streamline operations and improve regulatory compliance.

Increasing Adoption in Emerging Markets:

As biotechnology and pharmaceutical sectors expand in emerging markets, countries such as China, India, and South Korea are seeing increased adoption of single-use bioreactors. This growth is driven by government incentives to boost local biopharmaceutical production and meet growing healthcare demands. For instance, the Chinese government’s “Made in China 2025” initiative promotes investments in biotechnology, leading local manufacturers to adopt single-use systems for flexibility and faster setup times. Similarly, India has introduced policies to attract biopharma investments, with many companies adopting single-use technologies to improve cost efficiency and scale production quickly.

Focus on Sustainability and Waste Management:

The single-use nature of these bioreactors raises concerns about environmental impact, leading to innovations in sustainable materials and waste management solutions. Companies are increasingly using recyclable and biodegradable materials in their single-use systems. Thermo Fisher, for example, has launched initiatives to reduce the environmental footprint of its single-use products by promoting recycling programs. A study by the American Chemical Society indicates that sustainable materials and waste reduction strategies are becoming critical as biopharma companies look to balance operational efficiency with environmental responsibility, reflecting a broader industry commitment to sustainable practices.

Market Challenges Analysis:

High Capital and Operational Costs:

While single-use bioreactors (SUBs) offer cost savings in certain areas, such as reduced cleaning and sterilization needs, the initial costs for implementing single-use technology can be prohibitive for smaller firms. The materials and advanced components required to produce SUBs contribute to higher upfront expenses. Additionally, the cost of disposables, such as bags and filters, can add up significantly over time, impacting operational budgets. According to the Biotechnology Innovation Organization (BIO), smaller biopharma companies often face financial constraints when adopting new bioprocessing technologies, limiting the potential for widespread adoption.

Concerns Over Environmental Impact:

Single-use bioreactors generate substantial plastic waste, raising environmental concerns as they are used primarily in biopharmaceutical processes. Environmental regulatory bodies, such as the U.S. Environmental Protection Agency (EPA) and the European Chemicals Agency (ECHA), have highlighted the importance of sustainable practices and waste management in the industry. The high volume of disposable plastics associated with SUBs challenges manufacturers to find sustainable solutions, such as recycling programs or biodegradable materials, to minimize their environmental footprint. As environmental regulations become more stringent, companies may face increased pressure to address waste issues, which could affect long-term adoption.

Limited Scalability for Large-Volume Production:

While single-use bioreactors are well-suited for small to medium-scale production, they currently face challenges in scaling up to larger commercial volumes. Although some progress has been made, with systems reaching capacities of up to 2,000 liters, stainless steel bioreactors still dominate high-volume production due to their durability and cost efficiency in larger batches. The U.S. Food and Drug Administration (FDA) emphasizes that for commercial-scale biopharmaceutical manufacturing, regulatory compliance and process stability are paramount, making the switch from stainless steel to single-use systems challenging for large-scale operations that require high output and stringent quality control.

Concerns Over Extractables and Leachables:

The use of plastic components in single-use bioreactors raises concerns over extractables and leachables, which can contaminate the bioprocess and affect product safety and efficacy. Regulatory agencies, such as the FDA and the European Medicines Agency (EMA), require thorough testing to ensure that materials used in bioprocessing do not introduce contaminants into drug products. Testing for extractables and leachables adds complexity and cost to biopharmaceutical production, potentially deterring companies from fully adopting single-use systems in critical applications where product purity is essential.

Market Segmentation Analysis: 

By Type

The single-use bioreactor market is segmented by type into stirred-tank, wave-induced, and others. Stirred-tank bioreactors dominate the market due to their versatility and ability to accommodate various cell cultures, including microbial, animal, and plant cells. They offer efficient mixing and oxygen transfer, which makes them suitable for producing complex biologics like monoclonal antibodies. Wave-induced bioreactors are increasingly used for shear-sensitive cell lines, as they provide gentle mixing and are particularly favored in cell therapy applications. These types cater to different bioprocessing needs, depending on the specific characteristics required for each biopharmaceutical product.

By Technology

Segmenting by technology, single-use bioreactors are classified into microcarrier, suspension, and hybrid systems. Microcarrier-based systems are widely used for adherent cell cultures, often in vaccine production, as they allow cells to grow on tiny beads within the bioreactor. Suspension systems are predominant for mammalian cell cultures, which are commonly used in biologics manufacturing. Hybrid systems combine single-use components with reusable technologies, offering flexibility for scaling up production while maintaining cost efficiency. This diversity in technologies supports various biopharma production methods, enabling manufacturers to select systems based on specific process needs and scalability requirements.

By End User

The end-user segments for single-use bioreactors include biopharmaceutical companies, contract research organizations (CROs), and contract manufacturing organizations (CMOs). Biopharmaceutical companies are the primary users, leveraging single-use systems to expedite drug development and reduce overhead costs. CMOs also drive demand as they offer flexible, scalable solutions for clients needing rapid production capabilities, especially for small-batch biologics. CROs, which focus on early-stage research and clinical trials, benefit from single-use bioreactors for their ability to quickly switch between projects without the risk of cross-contamination. This segmentation highlights the broad appeal of single-use technologies across various stages of the biopharmaceutical lifecycle.

Segmentations:

• Single-use Bioreactor Systems
• Media Bags
• Filtration Assemblies
• Other Products

• Mammalian Cell
• Bacteria
• Yeast
• Other Cell Types

• Vaccines
• Monoclonal Antibodies
• Stem Cells
• Recombinant Proteins
• Other Molecule Types

• Pharmaceutical and Biopharmaceutical Industries
• Contract Research Organizations (CRO)
• Academic & Research Institutes
• Other End Users

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Regional Analysis:

North America

North America leads the global single-use bioreactor market, accounting for the largest share due to its well-established biopharmaceutical industry and significant investments in research and development. The United States, in particular, is a major contributor, with strong demand from pharmaceutical and biotechnology companies utilizing single-use bioreactors for drug development and commercial manufacturing. The region benefits from advanced regulatory frameworks and a high adoption rate of innovative bioprocessing technologies. The COVID-19 pandemic further accelerated adoption, as single-use systems proved essential in the rapid scale-up of vaccine production. North America’s market share reflects its commitment to maintaining a competitive edge in biopharmaceutical manufacturing through technological advancements and a focus on efficiency.

Europe

Europe represents a substantial portion of the single-use bioreactor market, driven by a strong emphasis on biosimilars and biologics production, particularly in countries like Germany, the United Kingdom, and France. The European Medicines Agency (EMA) supports the use of advanced bioprocessing systems, including single-use bioreactors, to enhance product quality and comply with stringent environmental and safety standards. European pharmaceutical companies are increasingly incorporating single-use technologies to improve flexibility and reduce costs, especially in high-value applications like cell and gene therapy. Europe’s position is bolstered by both regulatory support and a focus on innovation within the biopharma sector.

Asia-Pacific

The Asia-Pacific region is expected to witness the fastest growth, driven by expanding biopharmaceutical manufacturing capabilities and increased government support for biotechnology. China, Japan, South Korea, and India are key players, investing heavily in bioprocessing infrastructure to meet rising demand for biopharmaceuticals and biosimilars. Government initiatives, such as China’s “Made in China 2025,” emphasize self-sufficiency in biopharmaceutical production, fueling the adoption of single-use technologies. Additionally, the cost-efficiency and scalability of single-use bioreactors appeal to emerging biotech firms across the region, underscoring Asia-Pacific’s potential for continued expansion in this market.

Latin America and the Middle East & Africa

Latin America and the Middle East & Africa, though holding smaller shares of the market, show promising growth potential. Brazil, Mexico, and Saudi Arabia are key contributors, with growing biopharma industries and increased demand for localized vaccine production. The Middle East’s healthcare expansion and investments in life sciences have spurred adoption of single-use technologies, particularly in academic and research institutions exploring bioprocessing capabilities. As these regions continue to expand their biotechnology and biopharmaceutical sectors, the adoption of single-use bioreactors is expected to rise gradually, supported by favorable government initiatives and investments in biopharma infrastructure.

Key Player Analysis:

• Sartorius AG
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Merck KGaA
• Cytiva (formerly part of GE Healthcare)
• Pall Corporation
• Eppendorf SE
• Distek Inc.
• Getinge AB
• PBS Biotech Inc.

Competitive Analysis:

The single-use bioreactor market is highly competitive, with major players like Sartorius AG, Thermo Fisher Scientific, and Merck KGaA leading due to their extensive product portfolios, advanced bioprocessing technologies, and established relationships with biopharmaceutical manufacturers. These companies leverage strong R&D capabilities to develop scalable and flexible solutions that cater to the evolving needs of biologics production, especially in monoclonal antibodies and cell therapies. Smaller players, such as PBS Biotech and Distek Inc., focus on niche markets and innovative solutions to differentiate themselves, often targeting specific applications like cell and gene therapy. Market competition is further driven by the shift towards large-scale single-use systems and integration of automation technologies, allowing manufacturers to optimize production efficiency. Additionally, companies are increasingly focusing on sustainable solutions to address the environmental concerns associated with single-use systems. Overall, competitive dynamics are shaped by advancements in technology, regulatory compliance, and the growing demand for efficient, cost-effective bioproduction solutions.

Recent Developments:

• In 2024, Thermo Fisher introduced its 5,000-liter DynaDrive™ single-use bioreactor, designed for large-scale production. This advanced system offers up to a 10:1 turndown ratio, enabling flexible scale-up from 500 to 5,000 liters, which is ideal for high-volume biomanufacturing. The DynaDrive is equipped with multiple impellers that enhance oxygen transfer rates and mixing efficiency, critical for high cell-density processes and intensified bioprocessing applications.
• Merck launched enhancements to its Mobius® single-use bioreactor line in 2023, focusing on ease of use and flexibility. These updates include integrated real-time monitoring capabilities and improved bag materials that reduce the risk of contamination. The system is specifically designed for use in cell and gene therapy production, allowing biopharmaceutical companies to scale from clinical trials to commercial production while maintaining product quality and safety standards.
• ABEC expanded its portfolio in 2023 with the introduction of 4,000-liter and 6,000-liter single-use bioreactors, the largest on the market. These bioreactors cater to large-scale biomanufacturing needs, such as monoclonal antibody production. ABEC’s systems provide high scalability and reduce the need for multiple smaller units, which simplifies production processes and reduces operational costs.
• In 2022, Sartorius partnered with RoosterBio to enhance single-use bioreactor capabilities for cell and gene therapy. This collaboration focuses on developing intensified seed-train technologies that allow biopharma companies to use fewer bioreactors while achieving higher cell densities, streamlining the process from research to clinical and commercial production. The partnership also supports sustainable biomanufacturing by minimizing waste and reducing overall resource use.

Market Concentration & Characteristics:

The Single Use Bioreactor Market exhibits moderate concentration, with several key players dominating the industry. Major companies like Sartorius AG, Danaher Corporation, Thermo Fisher Scientific Inc., and Merck KGaA hold significant market shares. These industry leaders focus on innovation, product development, and strategic partnerships to maintain their competitive edge. The market is characterized by rapid technological advancements, with a strong emphasis on improving bioreactor efficiency, scalability, and integration with other bioprocessing systems. Product offerings range from small-scale systems (≤10 L) to large-scale bioreactors (>1,500 L), catering to diverse research and production needs. Geographically, North America leads the market, followed by Europe and Asia Pacific. The industry is witnessing increased adoption among contract development and manufacturing organizations (CDMOs), contract manufacturing organizations (CMOs), and small to medium-sized enterprises (SMEs). Key market drivers include the growing biologics and biosimilars markets, reduced capital investment requirements, and advantages over conventional bioreactors. However, challenges related to extractables and leachables, as well as regulatory hurdles, continue to shape market dynamics.

Report Coverage:

The research report offers an in-depth analysis based on Product, Cell Type, Molecule Type, and End User. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

1. Demand for single-use bioreactors will continue to grow as biopharmaceutical companies seek flexible and cost-effective solutions for biologics and cell therapy production.
2. The trend towards large-scale single-use systems will expand, driven by advancements that enable capacities of 2,000 liters or more, allowing for commercial-scale manufacturing.
3. Increased adoption of automation and real-time monitoring technologies will improve process control and efficiency.
4. Biopharma companies will continue to emphasize sustainability, encouraging manufacturers to develop recyclable and biodegradable bioreactor components to address environmental concerns.
5. Emerging markets, particularly in Asia-Pacific, are expected to see rapid growth as countries such as China and India expand their biomanufacturing capabilities to meet local and global demand.
6. The expansion of contract manufacturing organizations (CMOs) will support single-use bioreactor adoption.
7. Innovations in intensified processing, such as seed-train optimization, will reduce the number of bioreactors required, streamlining production while enhancing yield and quality.
8. The rise of personalized medicine and small-batch biologics production will drive demand for single-use systems that offer rapid setup and flexibility.
9. Strategic partnerships and collaborations will increase, with companies working together to improve single-use technologies and address market-specific needs in areas like cell and gene therapy.
10. Regulatory agencies will support the adoption of single-use bioreactors by endorsing technologies that promote product safety.

Rising Demand for Biologics and Personalized Medicine

The increasing prevalence of chronic diseases and the shift toward biologics, such as monoclonal antibodies and cell therapies, are driving adoption of single-use bioreactors. These systems enable flexible, small-batch production essential for personalized medicine and rapid drug development.

Cost-Efficiency and Operational Flexibility

Single-use bioreactors reduce capital and operational costs by eliminating the need for cleaning and sterilization, allowing for faster turnaround and lower water and labor usage. This makes them attractive for both established biopharma companies and emerging biotech startups seeking efficient production.

Expansion of Contract Manufacturing Organizations (CMOs)

CMOs are rapidly adopting single-use bioreactors to offer flexible, scalable manufacturing solutions for multiple clients, minimizing cross-contamination risks and enabling quick project transitions. This trend supports market growth as more biopharma companies outsource production.

Technological Advancements in Bioprocessing

Innovations such as sensor integration, automation, and real-time monitoring have improved process control, yield, and product quality in single-use bioreactors. These advancements make single-use systems increasingly viable for commercial-scale manufacturing.

Rapid Growth in Emerging Markets

Government incentives and investments in biotechnology in countries like China, India, and South Korea are accelerating the adoption of single-use bioreactors. Local manufacturers are leveraging these systems for cost-effective, scalable biopharmaceutical production to meet rising domestic and global demand.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.